Plant virus-based immunotherapy for enhancing host immune responses against solid tumors
University of California, San Diego has developed a novel intratumoral immunotherapy using cowpea mosaic virus (CPMV) to enhance immune responses against solid tumors, showing promise in overcoming tumor microenvironment immunosuppression and inducing systemic anti-tumor immunity.
Overview
The University of California, San Diego presents an innovative approach to cancer immunotherapy using the cowpea mosaic virus (CPMV) as an intratumoral treatment. This plant virus has demonstrated the ability to stimulate potent, systemic, and durable anti-tumor immunity. It uniquely overcomes the immunosuppressive environment within tumors, thereby facilitating both local and systemic adaptive anti-tumor responses. CPMV therapy promises broad clinical applicability as it shows efficacy across various tissue types and tumor models, including melanoma, breast cancer, and colon cancer. This therapy is not only effective on its own but also enhances the performance of existing therapies like T cell engagers (TCE) and chimeric antigen receptor (CAR)-T cell therapies.
Technical specifications
Key features:
- Utilizes cowpea mosaic virus (CPMV) for intratumoral immunotherapy
- Stimulates systemic and durable anti-tumor immunity
- Overcomes tumor microenvironment immunosuppression
- Induces immune memory to prevent tumor recurrence
- Effective across multiple cancer types and models
- Synergizes with other immunotherapies
Technology readiness level
The CPMV-based immunotherapy has reached Technology Readiness Level 5. It has been validated in preclinical models, including murine tumor models and canine cancer patients, demonstrating significant potential for further development and clinical application. Future validation efforts will focus on enhancing therapeutic efficacy in combination with other cancer immunotherapies.
About University of California, San Diego
UC San Diego is a comprehensive public research university in La Jolla, anchored by an integrated academic health system. On the east campus, the 23‑acre Science Research Park co‑locates corporate R&D with university programs and connects to the health sciences district, enabling daily interaction among scientists, clinicians, and companies. The Jacobs School’s Corporate Affiliates Program provides structured engagement and recruiting, while the Office of Innovation & Commercialization supports IP, licensing, and startup formation. The research enterprise is sustained by competitive federal funding, with recent awards exceeding $1.7B annually. Established commercialization pathways streamline sponsored research and help partners move from proof of concept to deployment.
delivered to your inbox.